A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 11 Jul 2017 Planned End Date changed from 14 Sep 2018 to 14 Jan 2019.
- 11 Jul 2017 Planned primary completion date changed from 14 Sep 2018 to 14 Jan 2019.
- 27 Jun 2017 Planned number of patients changed from 240 to 400.